16 completed, 14 recruiting, 6 active not recruiting, 3 not yet recruiting. 25 Phase 2, 17 Phase 1, 9 Phase 3.
Follow dinutuximab: new trials by email Literature Review of dinutuximab trials Research Report on dinutuximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 76 | 2027-06-25 | 2026-10-22 |
| NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab Radiation: 131I-MIBG, Dinutuximab, Vorinostat - Neuroblastoma | Phase 2 | Not yet recruiting | New Approaches to Neuroblastoma Therapy Consortium | 118 | 2026-12-31 | 2026-08-21 |
| Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors. Dinutuximab beta, Sirolimus and Irinotecan - Osteosarcomas, Bone Cancer | Phase 1 / Phase 2 | Not yet recruiting | University Hospital, Strasbourg, France | 89 | 2026-10-01 | 2026-10-01 |
| Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk Neuroblastoma Dinutuximab Beta, Induction chemotherapy - High Risk Neuroblastoma | Phase 1 | Recruiting | Chang Gung Memorial Hospital | 30 | 2026-07-01 | 2026-10-06 |
| Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children Chidamide Combined with Dinutuximab Beta, Irinotecan, and Temozolomide - Neuroblastoma (NB), Neuroblastoma in Children | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 27 | 2026-01-06 | 2026-10-01 |
| Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma Dinutuximab beta, temozolomide, irinotecan, autologous NK cell, irinotecan, temozolomide, dinutuximab beta, NK-cell product - Neuroblastoma (NB), Ganglioneuroblastoma | Phase 3 | Recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 5 | 2025-11-19 | 2026-01-29 |
| International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing Sarkoma Dinutuximab beta - High-risk GD2-Positive Ewing Sarcoma | Phase 1 | Not yet recruiting | Prof. Dr. Dirk Reinhardt | 18 | 2025-03-01 | 2025-02-21 |
| Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma Dinutuximab beta, chemotherapy treatment called GPOH, chemotherapy treatment called rapid COJEC - Neuroblastoma | Phase 1 | Recruiting | Princess Maxima Center for Pediatric Oncology | 38 | 2025-01-28 | 2025-07-08 |
| NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial Universal Donor (UD) TGFβi NK Cells, Temozolomide, Irinotecan - Neuroblastoma | Phase 2 | Recruiting | New Approaches to Neuroblastoma Therapy Consortium | 62 | 2024-12-16 | 2026-07-20 |
| A Multi-Arm, Platform Trial For Relapsed Neuroblastoma Bevacizumab, Dinutuximab beta, Irinotecan (drug) - Relapsed Neuroblastoma | Phase 1 / Phase 2 | Recruiting | University of Birmingham | 160 | 2024-11-11 | 2026-01-12 |
| Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Ganglioneuroblastoma, Nodular, Neuroblastoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 478 | 2024-04-19 | 2026-10-21 |
| Qarziba for Patients in Relapsed/Refractory High-grade Osteosarcoma Dinutuximab beta - Osteosarcoma in Children | Phase 2 | Suspended | Prof. Franca Fagioli | 22 | 2023-11-30 | 2023-11-18 |
| Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate - Neuroblastoma, Refractory Neuroblastoma | Phase 1 | Recruiting | Emory University | 24 | 2023-11-06 | 2025-12-26 |
| Rapid Administration Pilot for Infusing Dinutuximab Dinutuximab with Chemotherapy - Neuroblastoma | Phase 2 | Active not recruiting | Children's Hospital Los Angeles | 30 | 2022-11-29 | 2026-09-17 |
| NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab Natural Killer Cells, Temozolomide, Irinotecan - Relapsed Neuroblastoma, Refractory Neuroblastoma | Phase 1 / Phase 2 | Active not recruiting | Nationwide Children's Hospital | 31 | 2022-09-01 | 2026-09-16 |
| Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma Dinutuximab Beta, 13-cis-Retinoic Acid - High-risk Neuroblastoma | Phase 1 | Completed | BeiGene | 8 | 2022-06-07 | 2024-10-04 |
| Quadruple Immunotherapy for Neuroblastoma Natural killer cell, Dinutuximab beta, Interleukin-2 - Neuroblastoma Recurrent | Phase 2 | Recruiting | Hong Kong Children's Hospital | 29 | 2022-01-01 | 2025-09-15 |
| Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy) - High-Risk Neuroblastoma | Phase 1 | Recruiting | Jagiellonian University | 20 | 2021-12-01 | 2022-03-09 |
| Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma Dinutuximab Beta, Zoledronic acid, Interleukin-2 - Leiomyosarcoma | Phase 2 | Completed | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 7 | 2021-11-15 | 2025-08-17 |
| Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - High Risk Neuroblastoma, Recurrent Neuroblastoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 12 | 2021-08-31 | 2026-06-30 |
Showing 20 of 45. Sign in to see all of them.
Neuroblastoma (31) · Ganglioneuroblastoma (7) · Osteosarcoma (5) · Bone Neoplasms (2) · Brain Neoplasms (1) · Diffuse Intrinsic Pontine Glioma (1) · Ependymoma (1) · Glioblastoma (1) · Glioma (1) · Leiomyosarcoma (1) · Medulloblastoma (1) · Neoplasm, Residual (1) · Neoplasms (1) · Rhabdoid Tumor (1) · Rhabdomyosarcoma (1)
National Cancer Institute (NCI) (10) · New Approaches to Neuroblastoma Therapy Consortium (4) · Children's Oncology Group (3) · United Therapeutics (3) · University of Birmingham (2) · BeiGene (1) · Chang Gung Memorial Hospital (1) · Children's Hospital Los Angeles (1) · Eli Lilly and Company (1) · Emory University (1) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · Fundació Sant Joan de Déu (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Hong Kong Children's Hospital (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1)
United States (25) · Australia (11) · Canada (10) · New Zealand (8) · Austria (6) · France (6) · Germany (6) · Italy (6) · Puerto Rico (6) · Spain (6) · Belgium (5) · United Kingdom (5) · Denmark (3) · Netherlands (3) · Russia (3)
Araz Marachelian, MD, MS (2) · Mark Ranalli, MD (2) · Sara M Federico (2) · Alice L Yu (1) · Ami Desai, MD (1) · Ami V Desai (1) · Andrew Gilman (1) · Araz Marachelian (1) · Araz Marachelian, MD (1) · Claudia Pasqualini, MD PhD (1) · Daniel Cheuk (1) · Franca Fagioli, MD (1) · Frank Berthold, Prof. Dr. (1) · Holger Lode, MD, PhD (1)
PMID 15337804, PMID 20567002, PMID 20879881, PMID 22742881, PMID 28549783, PMID 32221013, PMID 32343642, PMID 34028986, PMID 34367149, PMID 34871104, PMID 35278766, PMID 35839426, PMID 36822669, PMID 36854071, PMID 37813959, PMID 37883734, PMID 38190578, PMID 38200233, PMID 40549985
U10CA180886 (9), U10CA098543 (3), 2019 (2), 2023 (2), 2014 (1), P01CA081403 (1), P01CA217959 (1), P30CA015704 (1), U01CA154967 (1), U10CA030969 (1), UM1CA228823 (1)